{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T13:57:22Z","timestamp":1780581442646,"version":"3.54.1"},"reference-count":51,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.clinthera.2021.02.003","type":"journal-article","created":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T20:03:03Z","timestamp":1616184183000},"page":"711-719","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Management of Primary Hyperparathyroidism With Severe Hypercalcemia During the COVID-19 Pandemic"],"prefix":"10.1016","volume":"43","author":[{"given":"Eman M.","family":"Alfadhli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2021.02.003_bib0001","doi-asserted-by":"crossref","first-page":"G57","DOI":"10.1530\/EJE-20-0385","article-title":"Management of calcium metabolic disorders and osteoporosis","volume":"183","author":"Gittoes","year":"2020","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.clinthera.2021.02.003_bib0002","first-page":"74","article-title":"Endocrine effects of COVID 19: Difficulties in the management of endocrine disorders from individual to societies","volume":"16","author":"Moroti","year":"2020","journal-title":"Acta Endocrinol"},{"key":"10.1016\/j.clinthera.2021.02.003_bib0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/jendso\/bvaa144","article-title":"SARS-CoV-2 (COVID-19) and the endocrine system","volume":"4","author":"Lundholm","year":"2020","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.clinthera.2021.02.003_bib0004","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.maturitas.2020.04.006","article-title":"Non-surgical management of primary hyperparathyroidism in the aging population","volume":"136","author":"Cipriani","year":"2020","journal-title":"Maturitas"},{"key":"10.1016\/j.clinthera.2021.02.003_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.nmni.2020.100738","article-title":"COVID-19: pathophysiology, diagnosis, complications and investigational therapeutics","volume":"37","author":"Azer","year":"2020","journal-title":"New Microbes New Infections"},{"key":"10.1016\/j.clinthera.2021.02.003_bib0006","doi-asserted-by":"crossref","first-page":"11287","DOI":"10.18632\/aging.103526","article-title":"Serum calcium as a biomarker of clinical severity and prognosis in patients with coronavirus disease 2019","volume":"12","author":"Sun","year":"2020","journal-title":"Aging"},{"key":"10.1016\/j.clinthera.2021.02.003_bib0007","doi-asserted-by":"crossref","DOI":"10.1177\/1470320320926899","article-title":"Hypertension is associated with increased mortality and severity of disease in COVID-19 pneumonia: A systematic review, meta-analysis and meta-regression","volume":"21","author":"Pranata","year":"2020","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"10.1016\/j.clinthera.2021.02.003_bib0008","series-title":"Hyperparathyroidism","first-page":"111","article-title":"Medical management of primary hyperparathyroidism","author":"Kearns","year":"2016"},{"issue":"Suppl 17","key":"10.1016\/j.clinthera.2021.02.003_bib0009","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1681\/ASN.V12suppl_1s3","article-title":"Hypercalcemic crisis","volume":"12","author":"Ziegler","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.clinthera.2021.02.003_bib0010","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.jamcollsurg.2007.11.010","article-title":"Hyperparathyroid crisis: Use of bisphosphonates as a bridge to parathyroidectomy","volume":"206","author":"Phitayakorn","year":"2008","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.clinthera.2021.02.003_bib0011","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1056\/NEJMcp1714213","article-title":"Primary hyperparathyroidism","volume":"379","author":"Insogna","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2021.02.003_bib0012","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1210\/jc.2014-1417","article-title":"Medical management of primary hyperparathyroidism","volume":"99","author":"Marcocci","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2021.02.003_bib0013","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0002-9343(97)00053-3","article-title":"Optimal dietary calcium intake in primary hyperparathyroidism","volume":"102","author":"Locker","year":"1997","journal-title":"Am J Med"},{"key":"10.1016\/j.clinthera.2021.02.003_bib0014","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.bone.2010.10.004","article-title":"Vitamin D deficiency influences histomorphometric features of bone in primary hyperparathyroidism","volume":"48","author":"Stein","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.clinthera.2021.02.003_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00198-016-3716-2","article-title":"Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus","volume":"28","author":"Khan","year":"2017","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinthera.2021.02.003_bib0016","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008874","article-title":"Exploring links between vitamin D deficiency and COVID-19","volume":"16","author":"Mohan","year":"2020","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.clinthera.2021.02.003_bib0017","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1210\/jc.2009-2384","article-title":"Skeletal effects of interventions in mild primary hyperparathyroidism: a meta-analysis","volume":"95","author":"Sankaran","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2021.02.003_bib0018","unstructured":"(UK) National Guideline Centre. Bisphosphonates. 2019."},{"key":"10.1016\/j.clinthera.2021.02.003_bib0019","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1210\/jc.2003-030908","article-title":"Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial","volume":"89","author":"Khan","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2021.02.003_bib0020","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1007\/s00198-014-3000-2","article-title":"Effects of alendronate and vitamin D in patients with normocalcemic primary hyperparathyroidism","volume":"26","author":"Cesareo","year":"2015","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinthera.2021.02.003_bib0021","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00774-013-0473-6","article-title":"Effect of parathyroidectomy versus risedronate on volumetric bone mineral density and bone geometry at the tibia in postmenopausal women with primary hyperparathyroidism","volume":"32","author":"Tournis","year":"2014","journal-title":"J Bone Miner Metab"},{"key":"10.1016\/j.clinthera.2021.02.003_bib0022","first-page":"729","article-title":"The efficacy and safety of intravenous bisphosphonates in the treatment of primary hyperparathyroidism complicated by hypercalcemia crisis","volume":"48","author":"Han","year":"2009","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"10.1016\/j.clinthera.2021.02.003_bib0023","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/jgs.15250","article-title":"Protective effect of denosumab on bone in older women with primary hyperparathyroidism","volume":"66","author":"Eller-Vainicher","year":"2018","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.clinthera.2021.02.003_bib0024","doi-asserted-by":"crossref","first-page":"K1","DOI":"10.1530\/EJE-14-0166","article-title":"Refractory hypercalcaemia secondary to parathyroid carcinoma: response to high-dose denosumab","volume":"171","author":"Karuppiah","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.clinthera.2021.02.003_bib0025","article-title":"Palliative treatment of uncontrollable hypercalcemia due to parathyrotoxicosis: denosumab as rescue therapy","volume":"2015","author":"Jumpertz von Schwartzenberg","year":"2015","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"10.1016\/j.clinthera.2021.02.003_bib0026","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1210\/clinem\/dgz322","article-title":"Risk for infections during treatment with denosumab for osteoporosis: a systematic review and meta-analysis\u200f","volume":"105","author":"Diker-Cohen","year":"2020","journal-title":"J Clin Endocrinol Metab\u200f"},{"key":"10.1016\/j.clinthera.2021.02.003_bib0027","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.bone.2008.04.007","article-title":"Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial","volume":"43","author":"Miller","year":"2008","journal-title":"Bone"},{"key":"10.1016\/j.clinthera.2021.02.003_bib0028","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s11914-019-00502-4","article-title":"Stopping Denosumab","volume":"17","author":"Lamy","year":"2019","journal-title":"Curr Osteoporos Rep"},{"key":"10.1016\/j.clinthera.2021.02.003_bib0029","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00198-017-4242-6","article-title":"Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study","volume":"29","author":"Zanchetta","year":"2018","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinthera.2021.02.003_bib0030","first-page":"1076","article-title":"Comparison of alendronate and raloxifene for the management of primary hyperparathyroidism","volume":"36","author":"Akbaba","year":"2013","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.clinthera.2021.02.003_bib0031","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1210\/jc.2002-020667","article-title":"Raloxifene lowers serum calcium and markers of bone turnover in postmenopausal women with primary hyperparathyroidism","volume":"88","author":"Rubin","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2021.02.003_bib0032","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/GL-2020-0524SUPPL","article-title":"American Association of Clinical Endocrinologists\/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis\u20142020 Update","volume":"26","author":"Camacho","year":"2020","journal-title":"Endocr Pract"},{"key":"10.1016\/j.clinthera.2021.02.003_bib0033","doi-asserted-by":"crossref","first-page":"e00819","DOI":"10.1128\/AAC.00819-20","article-title":"Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs","volume":"64","author":"Jeon","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2021.02.003_bib0034","unstructured":"Coronavirus: Using European Supercomputing, EU-funded resear [Internet]. Available at: https:\/\/ec.europa.eu\/commission\/presscorner\/detail\/en\/IP_20_890. Accessed December 26, 2020."},{"key":"10.1016\/j.clinthera.2021.02.003_bib0035","first-page":"3487","article-title":"Longitudinal changes in bone mineral density and bone turnover in postmenopausal women with primary hyperparathyroidism","volume":"81","author":"Guo","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2021.02.003_bib0036","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1016\/j.mayocp.2020.05.013","article-title":"Sex hormones and novel corona virus infectious disease (COVID)-19","volume":"95","author":"Al-Lami","year":"2020","journal-title":"Mayo Clinic Proc"},{"key":"10.1016\/j.clinthera.2021.02.003_bib0037","first-page":"162","article-title":"Pharmacology of the calcium sensing receptor","volume":"10","author":"Filopanti","year":"2013","journal-title":"Clin Cases Miner Bone Metab"},{"key":"10.1016\/j.clinthera.2021.02.003_bib0038","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1530\/EJE-14-0877","article-title":"Cinacalcet normalizes serum calcium in a double-blind randomized, placebo-controlled study in patients with primary hyperparathyroidism with contraindications to surgery","volume":"172","author":"Khan","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.clinthera.2021.02.003_bib0039","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1210\/jc.2008-2640","article-title":"Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism","volume":"94","author":"Marcocci","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2021.02.003_bib0040","doi-asserted-by":"crossref","first-page":"E9","DOI":"10.1210\/jc.2010-1221","article-title":"Cinacalcet HCl reduces hypercalcemia in primary hyperparathyroidism across a wide spectrum of disease severity","volume":"96","author":"Peacock","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2021.02.003_bib0041","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1530\/EJE-12-0117","article-title":"MEN1-related hyperparathyroidism: response to cinacalcet and its relationship with the calcium-sensing receptor gene variant Arg990Gly","volume":"167","author":"Filopanti","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.clinthera.2021.02.003_bib0042","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s12020-015-0696-5","article-title":"Cinacalcet therapy in patients affected by primary hyperparathyroidism associated to multiple endocrine neoplasia syndrome type 1 (MEN1)","volume":"52","author":"Giusti","year":"2016","journal-title":"Endocrine"},{"key":"10.1016\/j.clinthera.2021.02.003_bib0043","first-page":"1779","article-title":"Hypercalcemia of malignancy and new treatment options","volume":"11","author":"Sternlicht","year":"2015","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.clinthera.2021.02.003_bib0044","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1159\/000506100","article-title":"Cinacalcet for the treatment of humoral hypercalcemia of malignancy: an introductory case report with a pathophysiologic and therapeutic review","volume":"13","author":"Sheehan","year":"2020","journal-title":"Case Rep Oncol"},{"key":"10.1016\/j.clinthera.2021.02.003_bib0045","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1186\/s13256-016-1093-2","article-title":"Primary hyperparathyroidism in pregnancy treated with cinacalcet: a case report and review of the literature","volume":"10","author":"Vera","year":"2016","journal-title":"J Med Case Rep"},{"key":"10.1016\/j.clinthera.2021.02.003_bib0046","first-page":"e40","article-title":"A case of hyperparathyroidism treated with cinacalcet during pregnancy","volume":"5","author":"Bashir","year":"2019","journal-title":"AACE Clin Case Rep"},{"key":"10.1016\/j.clinthera.2021.02.003_bib0047","doi-asserted-by":"crossref","first-page":"66","DOI":"10.4081\/aiua.2015.1.66","article-title":"Use of cinacalcet in nephrolithiasis associated with normocalcemic or hypercalcemic primary hyperparathyroidism: results of a prospective randomized pilot study","volume":"87","author":"Brardi","year":"2015","journal-title":"Arch Ital Urol Androl"},{"key":"10.1016\/j.clinthera.2021.02.003_bib0048","article-title":"The effects of Cinacalcet in renal stone formers with primary hyperparathyroidism [in Italian]","volume":"33","author":"Vitale","year":"2016","journal-title":"G Ital Nefrol"},{"key":"10.1016\/j.clinthera.2021.02.003_bib0049","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1515\/JPEM.2004.17.7.931","article-title":"Calcitonin: physiological actions and clinical applications","volume":"17","author":"Inzerillo","year":"2004","journal-title":"J Pediatr Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2021.02.003_bib0050","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s12020-011-9459-0","article-title":"Cinacalcet hydrochloride in combination with alendronate normalizes hypercalcemia and improves bone mineral density in patients with primary hyperparathyroidism","volume":"39","author":"Faggiano","year":"2011","journal-title":"Endocrine"},{"key":"10.1016\/j.clinthera.2021.02.003_bib0051","first-page":"P155","article-title":"Denosumab increases bone mineral density in primary hyperparathyroidism treated with cinacalcet","volume":"35","author":"Gomez","year":"2014","journal-title":"Endocr Abstr"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291821001004?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291821001004?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:54:33Z","timestamp":1758963273000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291821001004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S0149291821001004"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2021.02.003","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Primary Hyperparathyroidism With Severe Hypercalcemia During the COVID-19 Pandemic","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2021.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}